Cb6f6b8d F5f3 4839 Be54 Dc2932ff649e 01
Topiramate
Product Images NDC 50436-1220
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 50436-1220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Cb6f6b8d F5f3 4839 Be54 Dc2932ff649e 02
This appears to be a graph or chart showing cumulative rates over time for an unknown variable. The y-axis values are 0.00 to 0.30 and the x-axis ranges from 100 to 450. The value "p = 0.0002" may indicate a statistical significance level. More information would be needed to provide a more precise description of the graph's content and context.*
Cb6f6b8d F5f3 4839 Be54 Dc2932ff649e 03
The text states the change in the average monthly migraine period rate after the double-blind phase while taking Topamax at a dosage of either 100 or 200 milligrams per day. It also includes statistical significance with p-values.*
Label Image (Lbl504361220)
This is a description of the medication named Topiramate. It is a 25mg/30 tablet strength medication that is manufactured by Cipla Ltd., in Kurkumbh, India. The tablets contain Topisrat USP 25g. The tablets should be dispensed in a tight container as defined in the USP and kept away from children, stored at a temperature range of 20-35 °C. The lot number for this medication is indicated as XXXXXX. The package insert contains dosage information, and this medication is only available with a prescription.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
